CollPlant Biotechnologies Ltd(CLGN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

CollPlant Biotechnologies Ltd (CLGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLGN at 15.6/100 on a 32-signal composite quality model, placing it at rank #2,852 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), CollPlant Biotechnologies Ltd reports quarterly revenue of $2.4M, net income of $-11.5M, free cash flow of $-9.4M. Top institutional holders of CLGN by reported 13-F value include PINNACLE ASSOCIATES LTD, VILLERE ST DENIS J, BROWN ADVISORY, based on the most recent SEC filings. CLGN trades on the Nasdaq exchange and files with the SEC under CIK 1631487. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CollPlant Biotechnologies Ltd directly from SEC EDGAR.